Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Other Working Capital Changes: 2009-2024

Historic Other Working Capital Changes for Madrigal Pharmaceuticals (MDGL) over the last 16 years, with Dec 2024 value amounting to $10.6 million.

  • Madrigal Pharmaceuticals' Other Working Capital Changes fell 257.26% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.5 million, marking a year-over-year increase of 60.45%. This contributed to the annual value of $10.6 million for FY2024, which is 1816.40% up from last year.
  • Madrigal Pharmaceuticals' Other Working Capital Changes amounted to $10.6 million in FY2024, which was up 1,816.40% from $555,000 recorded in FY2023.
  • Madrigal Pharmaceuticals' 5-year Other Working Capital Changes high stood at $10.6 million for FY2024, and its period low was -$138,000 during FY2020.
  • Its 3-year average for Other Working Capital Changes is $4.1 million, with a median of $1.3 million in 2022.
  • Per our database at Business Quant, Madrigal Pharmaceuticals' Other Working Capital Changes slumped by 55.85% in 2023 and then soared by 1,816.40% in 2024.
  • Madrigal Pharmaceuticals' Other Working Capital Changes (Yearly) stood at -$138,000 in 2020, then spiked by 335.51% to $325,000 in 2021, then soared by 286.77% to $1.3 million in 2022, then slumped by 55.85% to $555,000 in 2023, then surged by 1,816.40% to $10.6 million in 2024.